An observational study in COVID-19, Kidney Injury and Gene Amplification, sponsored by Instituto Nacional de Enfermedades Respiratorias. Completed at 1 site in Mexico. Open to male participants aged 15 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-06-27.
Sponsored by Instituto Nacional de Enfermedades Respiratorias · Observational
The involvement of the kidneys in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the outset of the pandemic was associated with high mortality rates worldwide. This was in part due to the generation of an inflammatory process and exacerbated oxidative stress. The present study was initiated to investigate the relationship between morphofunctional changes and gene expression in the kidney tissue of deceased Mexican patients prior to the initiation of vaccination.
The investigator designed a single-center, prospective, cohort study, to analyze and relate the morphofunctional changes and gene expression of inflammatory and oxidative stress molecules in the kidney tissue of men who died from severe COVID-19. A total of 40 percutaneous renal biopsies from deceased patients with severe acute respiratory syndrome coronavirus 2 infection were included in the study and divided into two a groups. One group was preserved in trizol to obtain RNA and total protein, while the remaining sample was fixed in formalin to be examined by staining with hematoxylin and eosin. The histopathological analysis was conducted by an experienced pathologist. The expression of molecules was evaluated by real-time polymerase chain reaction assay (nphs2, slc9a1, cx3cl1, havcr1, slc22a17, sod2, egf, timp2, hmox1, fabp1, and so forth). The following biomarkers were analyzed: interleukin-6, Arginase-1 (Arg-1), Dipeptidyl peptidase-4 (DPP-4), GSTT1, type I gamma-glutamyltransferase (GGT1), Occludin (OCL), CYP3A4, and Claudin-8 (CL-8). Additionally, Western blot analysis was conducted on claudin-5 (CL-5), occludin, HSP70, Nuclear factor erythroid 2-related factor-2 (NRF-2), superoxide dismutase-2 (SOD-2), nicotinamide adenine dinucleotide phosphate dehydrogenase 1 (NQO1), Gamma glutamylcysteine synthase (γ-GCL), and receptor for advanced glycation end products (RAGE). The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, with the subjects divided into two groups based on their eGFR: >60 or \<60 ml/min/1.73 m². The statistical analysis was conducted using the Stata program and GraphPad software, version 10.2.3.
7,775 studies on the registry are indexed under COVID-19; 482 are open to participants now.
This study's enrollment of 40 is below the median of 260 across 3,188 observational studies indexed under COVID-19.
Browse COVID-19 studies →Instituto Nacional de Enfermedades Respiratorias is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults >15 years old who died at the INER with a confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Fibrosis and sclerosis scores for identifying morphological changes in kidney tissue.
Morphological changes were evaluated by the fibrosis and sclerosis scores (mild, moderate and severe), using direct visualization of nephron compartments (glomerular and tubulointerstitial) of patients who died due to severe COVID-19.
Time frame: From the date of postmortem kidney biopsy until the date of histopathological report, in average seven days.
The estimated glomerular filtration rate for evaluating functional changes. The estimated glomerular filtration rate for evaluating functional changes.
Functional changes were calculated using the estimated glomerular filtration rate (\> 60 vs \< 60 ml/min/1.73m2) of patients who died due to severe COVID-19.
Time frame: From the date of arrival at the hospital until the date of death, in average one month.
Differential gene expression using polymerase chain reaction
Changes in differential gene expression in the kidney tissue of patients who died from due to severe COVID-19.
Time frame: From the date of postmortem kidney biopsy until the date of measure of differential gene expression, evaluated in 72 months.
Quantity of inflammatory molecules expressed in picograms of proteins.
Changes in the quantity of inflammatory molecules in the kidney tissue of patients who died due to severe COVID-19.
Time frame: From the date of postmortem kidney biopsy until the date of measure the inflammatory molecules expressed in the tissue, evaluated in 72 months.
Quantity of oxidative stress molecules expressed in picograms of proteins.
Changes in the quantity of oxidative stress molecules expressed in the kidney tissues of patients who died due to severe COVID-19.
Time frame: From the date of postmortem kidney biopsy to the date of measure of oxidative stress molecules expressed in the tissue report, evaluated in 72 months.
Ran from Mar 2020 to primary completion in Dec 2020, 9 months.
Of 1,625 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 29. This study's 9 months is below that.
Counting every sponsor, half of 1,750 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Nacional de Enfermedades Respiratorias